How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

IF

NASDAQ:IFRX
Get a brief AI stock analysisSaves ~ 15 minutes of your time

IF

InflaRx NVNASDAQ IFRX Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is IFRX undervalued compared to its fair value?

The fair value of IFRX stock is hidden USD. Relative to the market price of 1.66 USD InflaRx NV is hidden.

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered ...[More about valuation]

InflaRx NV Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.099 $B

Price:

1.66 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.164

FINANCIALS

InflaRx NV financial for reporting period

Income Statement

0 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.012 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0097 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0 B 100%
-0.0002 B -512%
-0.012 B -34652%
-0.0097 B -26796%

Balance Sheet

0.11 B
0.095 B

0.0011 B

Financial Position Analysis

Assets

0.11 B
Current Assets
0.1 B
Total non-current assets
0.0041 B

Total current liabilities
0.012 B
Total non-current liabilities
0.0008 B

Cash Flow Statement

-0.015 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.015 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

InflaRx NV fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-37 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-350 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-34 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is IFRX attractive for investment based on fundamental analysis?

IFRX stock rating is hidden. InflaRx NV is a hidden by Eyestock methodology.

Get IFRX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-41 601

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

9.703

Debt / Equity ratio:

0.011

ROE:

-37

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

IFRX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for IFRX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

InflaRx NV competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

InflaRx NV dividends

IFRX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About IFRX stock

About the company InflaRx NV

Market cap $B

0.099

Dividend yield

Shares outstanding

44.7038 B

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

IFRX profile

  • Ticker

    IFRX

  • Country

    Germany

  • Exchange

    XNAS - Nasdaq

  • Report currency

    EUR - Euro

  • IPO date

    16 November 2017

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    59

  • City

    Jena

  • Address

    Winzerlaer Str. 2

  • Cusip

    N44821101